# A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia

> **NCT01678924** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 280 (actual)

## Conditions studied

- Neuralgia, Postherpetic

## Interventions

- **DRUG:** AGN-214868
- **DRUG:** AGN-214868 Placebo (Vehicle)

## Key facts

- **NCT ID:** NCT01678924
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-05
- **Final completion:** 2015-09
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2020-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01678924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01678924, "A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01678924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*